.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Federal Trade Commission
Covington
Chinese Patent Office
Accenture
McKinsey
Dow
Baxter
Cantor Fitzgerald
Queensland Health

Generated: June 28, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,596,756

« Back to Dashboard

Which drugs does patent 6,596,756 protect, and when does it expire?


Patent 6,596,756 protects CYMBALTA and is included in one NDA. There have been two Paragraph IV challenges on Cymbalta.

Protection for CYMBALTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirteen patent family members in fourteen countries.

Summary for Patent: 6,596,756

Title: Treatment of fibromyalgia
Abstract:A method of using N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine to treat persistent pain.
Inventor(s): Goldstein; David Joel (Indianapolis, IN), Iyengar; Smriti (Carmel, IN), Simmons; Rosa Marie Ademe (Carmel, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:09/786,836
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Lilly
CYMBALTA
duloxetine hydrochloride
CAPSULE, DELAYED REL PELLETS;ORAL021427-001Aug 3, 2004ABRXYesNo6,596,756*PED► SubscribeY
Lilly
CYMBALTA
duloxetine hydrochloride
CAPSULE, DELAYED REL PELLETS;ORAL021427-002Aug 3, 2004ABRXYesNo6,596,756*PED► SubscribeY
Lilly
CYMBALTA
duloxetine hydrochloride
CAPSULE, DELAYED REL PELLETS;ORAL021427-004Aug 3, 2004ABRXYesYes6,596,756*PED► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,596,756

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany199 31 989Sep 09, 1999
PCT Information
PCT FiledSeptember 10, 1999PCT Application Number:PCT/US99/20986
PCT Publication Date:March 23, 2000PCT Publication Number: WO00/15223

International Patent Family for Patent: 6,596,756

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal1113797► Subscribe
Japan2002524513► Subscribe
Spain2335067► Subscribe
European Patent Office1113797► Subscribe
Denmark1113797► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Julphar
Queensland Health
McKinsey
Boehringer Ingelheim
Novartis
Healthtrust
US Department of Justice
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot